SpyGlass Pharma

SGP

Current ValuationThe current P/E ratio is -14.68, above the reasonable range, cheaper than 7.48% of the time in the past 1 years, and the industry ranks 201/256, the industry Median -1.14.

-14.68xP/E
Stock price$24.60Earnings per share$-1.68

Historical Valuation

P/E ratioTypical rangeMedian

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
0285684112

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x20x40x60x80x100x
P/E ratio
Name/Symbol
TAKUSTakeda Pharmaceutical Company
-59.31x154.63%$61.95B
BAYRYUSBayer
-23.64x--$47.63B
BAYZFUSBayer Aktiengesellschaft
-23.80x--$47.94B
VTRSUSViatris
-51.07x107.68%$20.97B
ELANUSElanco Animal Health
-58.98x129.36%$11.74B
VREOFUSVIREO GROWTH INC
-127.52x--$8.56B
AXSMUSAxsome Therap
-42.59x21.51%$8.16B
BLTEUSBelite Bio
-57.97x29.87%$5.93B
CURLFUSCuraleaf Holdings, Inc.
-112.26x--$5.84B
MANEUSVeraDermics
-48.99x97.44%$5.11B
RGCUSRegencell Bioscience
-425.53x--$4.98B
DFTXUSDefinium Therapeutics
-12.52x54.37%$4.43B
EWTXUSEdgewise Therapeutics
-20.88x207.38%$4.12B
AMLXUSAmylyx Pharmaceuticals
-22.55x1.76%$3.43B
TARSUSTarsus Pharmaceuticals
-65.62x201.10%$3.05B
ELVNUSEnliven Therapeutics
-26.77x5.59%$2.84B
MBXUSMBX Biosciences
-24.23x31.12%$2.53B
BHCUSBausch Health
-2.15x569.84%$2.36B
SUPNUSSupernus Pharma
-21.07x66.18%$2.32B
PRGOUSPerrigo
-1.29x100.10%$2.23B

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.